Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, mono-center phase I/II study designed to determine the maximum
tolerated dose (MTD) and dose-limiting toxicities (DLT) of RAD001 in combination with
carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic
breast cancer. Additionally, the study is designed to characterize the safety, the
tolerability and efficacy of this study.